The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers

被引:25
|
作者
Nakasone, Y
Inoue, T
Oriuchi, N
Takeuchi, K
Negishi, A
Endo, K
Mogi, K
机构
[1] Gunma Univ, Fac Med, Dept Oral & Maxillofacial Surg, Maebashi, Gumma 3718511, Japan
[2] Gunma Univ, Fac Med, Dept Nucl Med, Maebashi, Gumma 3718511, Japan
[3] Takasaki Univ Hlth Welf, Takasaki, Gumma, Japan
关键词
oral cancer; FDG-PET; SUV; cervical lymph node metastasis;
D O I
10.1007/BF02988503
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: The aim of this study,is to clarify the clinical utility of 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) positron emission tomography (PET) in determining the TNM classification in patients with oral cancer. Methods: Twenty-five consecutive patients (14. male and 11 female; age range, 40 yr to 86 yr) with oral cancer were included in this study. The diagnostic accuracy for detecting cervical lymph nodes was investigated by comparing the results of CT and/or MRI and physical findings. For the semi-quantitative analysis, the tumor standardized uptake value (SUV) and tumor to background SUV ratio (T/B ratio) were assessed in primary tumors and cervical lymph nodes. Results: All primary lesions were visualized on FDG-PET images. Even though artifacts from dental materials near the lesion hampered the delineation of primary tumors on CT/MRI, the extent of primary tumors was accurately assessed by FDG-PET. The SUV and T/B ratio in the primary tumor classified in higher T grade (T3 and T4) was significantly higher than that in lower T grade (T1 and T2) (mean +/- SD of SUV; 8.32 +/- 2.199 vs. 5.15 +/- 3.77, p < 0.01, mean SD of T/B ratio; 6.96 +/- 3.23 vs. 3.61 +/- 2.76, p < 0.01). The SUV and T/B ratio of metastatic lymph nodes were also significantly higher than those of normal lymph nodes (mean +/- SD of SUV; 3.39 +/- 1.69 vs. 1.55 +/- 0.57, p < 0.00 1, mean +/- SD of T/B ratio; 2.46 +/- 1.08 vs. 1.03 +/- 0.22, p < 0.001). Among these three methods, FDG-PET in conjunction with CT/MRI showed the highest accuracy of 92%, but there were no significant differences in diagnostic accuracy among the three methods. For the semiquantitative analysis, a threshold SUV of 2.0 provided 100% sensitivity 82% specificity, and 88% accuracy. Furthermore, a threshold T/B ratio of 1.5 provided 100% sensitivity, 100% specificity, and 100% accuracy. Regarding the detection of distant metastasis, there was one positive result in FDG-PET showing distant pulmonary metastasis. Conclusions: Whole-body FDG-PET is an effective and convenient diagnostic tool for the evaluation of tumor staging in patients with oral cancer. Tumor staging by whole-body FDG-PET may, in fact, supplement the conventional staging by means of CT/MRI and physical findings.
引用
收藏
页码:505 / 512
页数:8
相关论文
共 50 条
  • [1] The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers
    Yoshiki Nakasone
    Tomio Inoue
    Noboru Oriuchi
    Kazuo Takeuchi
    Akihide Negishi
    Keigo Endo
    Kenji Mogi
    [J]. Annals of Nuclear Medicine, 2001, 15 : 505 - 512
  • [2] Whole-body tumor staging: MRI or FDG-PET/CT?
    Antoch, G
    Vogt, FM
    Bockisch, A
    Ruehm, SG
    [J]. RADIOLOGE, 2004, 44 (09): : 882 - 888
  • [3] Accuracy of whole-body FDG-PET/CT for tumor staging in oncology
    Antoch, G
    Saoudi, N
    Freudenberg, LS
    Kuehl, H
    Mueller, SP
    Beyer, T
    Bockisch, A
    Debatin, JF
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S285 - S285
  • [4] Whole-body tumor staging: MRI or FDG-PET/CT? [Ganzkörpertumorstaging: MRT oder FDG-PET/CT?]
    Antoch G.
    Vogt F.M.
    Bockisch A.
    Ruehm S.G.
    [J]. Der Radiologe, 2004, 44 (9): : 882 - 888
  • [5] Value of whole-body FDG-PET in recurrent ovarian cancers
    Torizuka, T
    Nobezawa, S
    Nagashima, S
    Maeda, M
    Ouchi, Y
    Kanno, T
    Futatsubashi, M
    Yoshikawa, E
    Okada, H
    [J]. POSITRON EMISSION TOMOGRAPHY IN THE MILLENNIUM, 2000, 1197 : 191 - 198
  • [6] Role of whole-body FDG-PET in management of patients with recurrent ovarian cancers.
    Torizuka, T
    Nobezawa, S
    Nagashima, S
    Maeda, M
    Kanno, T
    Futatsubashi, M
    Yoshikawa, E
    Okada, H
    Ouchi, Y
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 303P - 303P
  • [7] Value of whole-body FDG-PET in the routine staging of malignant melanoma
    Bender, H
    Frohmann, JP
    Grapow, M
    Hamad, K
    Schomburg, AS
    Reinhold, U
    Willkomm, P
    Gruenwald, F
    Ruhlmann, J
    Biersack, HJ
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 331 - 331
  • [8] Value of whole-body FDG-PET in the routine staging of malignant melanoma
    Bender, H
    Hamad, K
    Frohmann, JP
    Grapow
    Schomburg, AS
    Reinhold, U
    Palmedo, H
    Klemm, E
    Gruenwald, F
    Menzel, C
    Ruhlmann, J
    Biersack, HJ
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (05) : 610 - 610
  • [9] Whole-body FDG-pet for surgical staging of colorectal liver metastases
    Francis, DL
    Arulampalam, TH
    Visvikis, D
    Costa, DC
    Ell, PJ
    Taylor, I
    [J]. BRITISH JOURNAL OF SURGERY, 2002, 89 : 58 - 59
  • [10] The incremental value of whole-body FDG-PET Patlak imaging in the assessment of tumor patient
    Yao, Shulin
    Xu, Baixuan
    Li, Chenwei
    Wu, Runze
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60